Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D00446 (Sucralfate)
 278 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pharmacologic management of peptic ulcer disease continues to evolve with the introduction of diverse types of new therapeutic agents. The ideal aims of treatment of peptic ulcer disease are to relieve pain, heal the ulcer, and delay ulcer recurrence. This article provides a broad perspective on the pharmacology and therapeutic actions of antiulcer drugs. To date, no drug meets all goals of therapy. Drug treatment of peptic ulcers is targeted at either counteracting aggressive factors or stimulating the mucosal defense. Drugs that inhibit or neutralize gastric acid secretion include histamine H2-receptor antagonists, proton pump inhibitors, anticholinergics, prostaglandins, and antacids. H2-receptor antagonists have become first-line drugs for treatment of uncomplicated duodenal ulcers, gastric ulcers, prevention of ulcer relapse, and mild esophagitis. However, H2-receptor antagonists, like other gastric antisecretory/antiulcer drugs, have high rates of ulcer recurrence following discontinuation of therapy. They therefore need to be administered continuously in patients prone to such recurrences. Omeprazole has emerged as a major drug for the treatment of severe erosive esophagitis, refractory ulcers, and Zollinger-Ellison syndrome. The major disadvantage of proton pump inhibitors is the concern for their long-term safety. The roles of M1-antimuscarinic agents and antacids have not been fully defined. Misoprostol, effective for the treatment of gastric and duodenal ulcers, is now the only drug that prevents ulcers induced by nonsteroidal anti-inflammatory drugs. Mucosal protective drugs that do not inhibit gastric acid secretion include sucralfate and organic bismuth salts. Sucralfate is a nonsystemic, well-tolerated, effective drug for treatment of duodenal ulcers and prevention of duodenal ulcer relapse. The organic bismuth salt bismuth subcitrate is efficacious in the treatment of duodenal and gastric ulcers. Furthermore, it has also been established that it alters the course of ulcer recurrence. However, bismuth encephalopathy is a major toxicity concern that needs to be addressed.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Drugs for treatment of peptic ulcers. 135 99

Sucralfate as well as colloidal bismuth subcitrate (CBS) and probably also bismuth subsalicylate (BBS) are effective in the acute treatment of peptic ulcer disease. Sucralfate also has positive effects upon symptoms and healing of peptic lesions in reflux esophagitis. Healing rates in gastric and duodenal ulcers are equal to those obtained with H2-antagonists. Side effects are rare, transient and generally mild. Therapy with bismuth compounds should be restricted to 4-8 weeks (cave: bismuth encephalopathy). Healing rates of smokers with duodenal ulcers were the same as in non-smokers during sucralfate therapy. Sucralfate seems to be useful in the treatment (prophylaxis?) of NSAID-induced lesions in the upper gastrointestinal tract. The question of different recurrence rates in peptic ulcer disease after various kinds of medical treatment still remains open. The relationship between the etiology of peptic ulcer disease and Campylobacter pylori infection, as well as possible medical and therapeutic consequences, should be further investigated.
 ...
PMID:Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease. 265 80